TruCOMMS-CE Mark Approval

Aortech International PLC
21 August 2000

                                 
                     AorTech International plc
                                 
                    TruCOMMS - CE Mark approval
                                 
AorTech  International  plc,  the Scottish-based  manufacturer  of
cardiovascular  devices, announces European  Regulatory,  CE  Mark
approval  in  respect of TruCOMMS, the Continuous  Cardiac  Output
Monitoring System.

CE  Mark  approval enables AorTech to commence marketing  TruCOMMS
throughout  Europe and initially it will be targeted  towards  UK,
Germany and Italy. This follows on from FDA approval last year for
the North American market place.

Dr. Peter Duijst, AorTech's Medical Director, commented:

'With  the satisfactory conclusion of final clinical trials,  held
in conjunction with Papworth Hospital, Cambridge, UK, the TruCOMMS
system  represents  a  major breakthrough in  monitoring  patients
cardiac  output  both during and after surgery.   In  addition  to
obtaining   European  Regulatory  Approval  for  our  product,   a
presentation on TruCCOMS at the Annual Meeting of the  Association
of Cardio Thoracic Anaesthetists held in Cambridge last April, won
first  prize, TruCCOMS being described as a safe and effect device
for   continuous  real  time  monitoring  of  cardiac  output   on
critically ill patients.

'Recognising the tremendous advantages, which include ease of  use
and potential cost savings over existing heart monitoring systems,
several  major hospitals in Italy, Germany and the United Kingdom,
have requested our product for use both during and after surgery.

'The  main  clinical advantage of TruCOMMS over other  systems  is
through  the immediacy of its response to cardiac output  changes.
Those  in  the  medical field who deal with critical and  surgical
care  patients can for the first time monitor cardiac  performance
directly,  enabling the immediate recognition of  any  changes  in
cardiac  output, including during surgery - such technology  could
help save lives.'


Enquiries:
AorTech   International   plc                       01698 746699
Eddie McDaid, Managing Director

Ian Cameron, Finance Director
Dr. Peter Duijst, Medical & Regulatory Director

College  Hill Associates                            0207 4572020
Michael Padley / Nicholas Nelson

                          www.aortech.com

Copies of this statement will be available for a period of 14 days
               from the Company's registered office:
  Phoenix Cresent, Strathclyde Business Park, Bellshill, Scotland
                              ML4 3NJ